Factor | Median overall survival (range)a | Univariate P value | Multivariate P value | Hazard ratio (95% confidence ratio) |
---|---|---|---|---|
Cirrhosis | 0.506 | |||
Yes, n = 10 | 56 (29 to 83) | |||
No, n = 17 | 77 (27 to 127) | |||
Vascular invasion | 0.020 | 0.048 | 4.477 (1.013 to 19.789) | |
Yes, n = 9 | 30 (22 to 38) | |||
No, n = 18 | 72 (43 to 101) | |||
Multiple tumors | 0.469 | |||
Yes, n = 5 | 56 (35 to 77) | |||
No, n = 22 | 72 (12 to 132) | |||
Size >5 cm | 0.448 | |||
Yes, n = 14 | 31 (0 to 73) | |||
No, n = 13 | 72 | |||
Underlying liver disease | 0.652 | |||
Nonalcoholic fatty liver disease, n = 13 | 30 | |||
Hepatitis C, n = 7 | 77 | |||
Alcoholic hepatitis, n = 2 | 22 | |||
Transformed adenoma, n = 2 | Not reached | |||
Other, n = 3b | 31 | |||
Sex | 0.275 | |||
Male, n = 14 | 72 (35 to 109) | |||
Female, n = 13 | 43 (26 to 60) | |||
Age | Not estimable | 0.099 | ||
American Joint Committee on Cancer stage | 0.212 | |||
I, n = 16 | 72 (8 to 136) | |||
II, n = 8 | 31 (29 to 33) | |||
III, n = 3 | 136 | |||
Grade | 0.427 | |||
1, n = 13 | 72 (43 to 102) | |||
2, n = 8 | 30 | |||
3, n = 4 | Not estimable | |||
Unknown, n = 2 | 13 | |||
Serum α-fetoprotein concentration | Not estimable | 0.099 | ||
Model for End-Stage Liver Disease score | Not estimable | 0.482 | ||
Higher IGF-1 expression in adjacent liver than tumor | 0.006 | 0.040 | 7.889 (1.096 to 56.761) | |
Yes, n = 3 | 22 (0 to 54) | |||
No, n = 24 | 72 (37 to 107) |